Neufeld Leah R 4

What Happened
Leah R. Neufeld, Chief People Officer of Immuneering Corp (IMRX), was granted 140,000 derivative awards (an equity grant/option-style award) on February 3, 2026. The Form 4 lists an acquisition price of $0.00 for the award (reported as $0 in the filing). This was a grant/award, not a purchase or sale.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (filed timely, within two business days).
• Transaction type/code: Grant/Award (A), derivative.
• Amount: 140,000 shares (derivative). Price per share listed: $0.00 (grant entry).
• Shares owned after transaction: Not reported in this filing.
• Footnote: The award vests and becomes exercisable in equal monthly installments over a four-year period commencing February 1, 2026, and will be fully vested and exercisable on January 1, 2030.
• No exercise or sale was reported in this filing.

Context
This is a compensation-related equity grant (a derivative award) that vests over time; it does not immediately increase public float or represent an open-market purchase or sale. Such awards are common for executive compensation and retention; they become more relevant to market holdings if/when vested options are exercised or shares are issued.